{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T06:48:49Z","timestamp":1782283729938,"version":"3.54.5"},"reference-count":37,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:00:00Z","timestamp":1782259200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Outcomes in chronic myeloid leukemia (CML) remain heterogeneous despite effective BCR::ABL1 tyrosine kinase inhibitors (TKIs). Somatic mutations in epigenetic regulators, particularly additional sex combs-like 1 (ASXL1), have been implicated in adverse prognosis, but their clinical impact in CML has not been systematically defined. Methods: A systematic review was conducted using CINAHL, EMBASE, MEDLINE Ultimate, and PubMed from inception through August 2025. A total of 1339 records were identified; the eligible studies included adult and pediatric patients with chronic and advanced-phase (accelerated or blast) CML. After duplicate removal and screening, 11 studies met the inclusion criteria; these included adult patients only and were included in a qualitative synthesis and meta-analysis. ASXL1 mutation status was assessed using validated molecular methods. The outcomes included the molecular response, cytogenetic response, survival, and treatment resistance. Random-effects models were used to calculate the pooled odds ratios (ORs) with 95% confidence intervals (CIs). Statistical heterogeneity was assessed using the I2 statistic. Results: Across the included studies, ASXL1 mutations were detected in approximately 15% of patients. At 12 months, patients with ASXL1 mutations had significantly lower odds of achieving a major molecular response (MMR) compared with ASXL1-wildtype patients (OR 0.29; 95% CI 0.16\u20130.51; p &lt; 0.0001; I2 = 30%). No statistically significant difference was observed in the complete cytogenetic response (CCyR) (OR 0.30; 95% CI 0.02\u20135.31; p = 0.41; I2 = 68%). Compared with patients harboring other non-ASXL1 somatic mutations, an ASXL1 mutation was not associated with a significant difference in MMR (OR 0.49; 95% CI 0.23\u20131.05; p = 0.067; I2 = 0%). Conclusions: ASXL1 mutations may be associated with an inferior molecular response to TKI therapy in CML, supporting their role as an adverse prognostic biomarker. These findings highlight the potential value of incorporating myeloid mutation profiling into future CML risk-stratification strategies.<\/jats:p>","DOI":"10.3390\/cancers18132041","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T05:37:17Z","timestamp":1782279437000},"page":"2041","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prevalence and Prognostic Impact of ASXL1 Somatic Mutation in Patients with Chronic Myeloid Leukemia: A Systematic Review and Meta-Analysis"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8207-047X","authenticated-orcid":false,"given":"Rita","family":"Ahmad","sequence":"first","affiliation":[{"name":"Internal Medicine, University of North Dakota, Fargo, ND 58104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0577-7295","authenticated-orcid":false,"given":"Motaz","family":"Almahmood","sequence":"additional","affiliation":[{"name":"Tower Health, Internal Medicine, Phoenixville, PA 19460, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasha","family":"Kaddoura","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Heart Hospital, Hamad Medical Corporation, Doha 3050, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Ali","family":"Tariq","sequence":"additional","affiliation":[{"name":"Tower Health, Internal Medicine, Phoenixville, PA 19460, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7579-4923","authenticated-orcid":false,"given":"Ayman Abdullah","family":"Dalol","sequence":"additional","affiliation":[{"name":"College of Medicine, Qatar University, Doha 2713, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8288-8368","authenticated-orcid":false,"given":"Marrita","family":"Rabadi","sequence":"additional","affiliation":[{"name":"College of Medicine, Qatar University, Doha 2713, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0380-6364","authenticated-orcid":false,"given":"Aadhila Abbas","family":"Manthiri","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Qatar University, Doha 2713, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulrahman F.","family":"Al-Mashdali","sequence":"additional","affiliation":[{"name":"Hematology Department, National Center for Cancer Care and Research (NCCCR), Doha 3050, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hatem","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Tower Health, Internal Medicine, Phoenixville, PA 19460, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0622-8455","authenticated-orcid":false,"given":"Mohammed","family":"Abdulgayoom","sequence":"additional","affiliation":[{"name":"Hematology Department, National Center for Cancer Care and Research (NCCCR), Doha 3050, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayah","family":"Al Qaryoute","sequence":"additional","affiliation":[{"name":"School of Medicine, Appalachian State University, Boone, NC 28608, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Westall","sequence":"additional","affiliation":[{"name":"School of Medicine, University of North Dakota, Fargo, ND 58104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9702-8485","authenticated-orcid":false,"given":"Fadi","family":"Haddad","sequence":"additional","affiliation":[{"name":"MD Anderson Cancer Center, Department of Leukemia, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shehab F.","family":"Mohamed","sequence":"additional","affiliation":[{"name":"Hematology Department, National Center for Cancer Care and Research (NCCCR), Doha 3050, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1002\/ajh.27443","article-title":"Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring","volume":"99","author":"Jabbour","year":"2024","journal-title":"Am. J. Hematol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1038\/s41375-025-02664-w","article-title":"2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia","volume":"39","author":"Apperley","year":"2025","journal-title":"Leukemia"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1038\/s41375-023-02048-y","article-title":"European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia","volume":"37","author":"Cross","year":"2023","journal-title":"Leukemia"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1200\/JCO.2011.38.6565","article-title":"Assessment of BCR-ABL1 Transcript Levels at 3 Months Is the Only Requirement for Predicting Outcome for Patients with Chronic Myeloid Leukemia Treated with Tyrosine Kinase Inhibitors","volume":"30","author":"Marin","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Bourne, G., Bhatia, R., and Jamy, O. (2024). Treatment-Free Remission in Chronic Myeloid Leukemia. J. Clin. Med., 13.","DOI":"10.3390\/jcm13092567"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1200\/JCO.23.01647","article-title":"European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free Remission","volume":"42","author":"Mahon","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1080\/10428194.2021.1894652","article-title":"Mutational landscape of chronic myeloid leukemia: More than a single oncogene leukemia","volume":"62","author":"Kankainen","year":"2021","journal-title":"Leuk. Lymphoma"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1182\/blood-2018-02-832253","article-title":"Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease","volume":"132","author":"Branford","year":"2018","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1182\/blood-2020-136962","article-title":"Mutated Cancer-Related Genes Detected at Diagnosis of CML and a Novel Class of Variant Associated with the Philadelphia Translocation Are Both Independent Predictors of Inferior Outcomes","volume":"136","author":"Shanmuganathan","year":"2020","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e559","DOI":"10.1038\/bcj.2017.36","article-title":"Frequent somatic mutations in epigenetic regulators in newly diagnosed chronic myeloid leukemia","volume":"7","author":"Togasaki","year":"2017","journal-title":"Blood Cancer J."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1182\/blood-2018-07-862698","article-title":"Non-Ph variants in CML: Guilty drivers?","volume":"132","author":"Mustjoki","year":"2018","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.3324\/haematol.2019.231753","article-title":"Are we ready to use precision medicine in chronic myeloid leukemia practice?","volume":"104","author":"Kim","year":"2019","journal-title":"Haematologica"},{"key":"ref_14","first-page":"2380","article-title":"Impact of additional genetic abnormalities at diagnosis of chronic myeloid leukemia for first-line imatinib-treated patients receiving proactive treatment intervention","volume":"108","author":"Shanmuganathan","year":"2023","journal-title":"Haematologica"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Jain, A.G., Dalgetty, M., and Cortes, J.E. (2025). Is there a best frontline therapy in chronic myeloid leukemia?. Haematologica, Early view.","DOI":"10.3324\/haematol.2025.287813"},{"key":"ref_16","first-page":"942","article-title":"Somatic variant profiling in chronic phase pediatric chronic myeloid leukemia","volume":"109","author":"Behrens","year":"2023","journal-title":"Haematologica"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Gualdi-Russo, E., and Zaccagni, L. (2026). The Newcastle\u2013Ottawa Scale for Assessing the Quality of Studies in Systematic Reviews. Publications, 14.","DOI":"10.3390\/publications14010004"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41408-022-00742-1","article-title":"Prognostic impact of ASXL1 mutations in chronic phase chronic myeloid leukemia","volume":"12","author":"Bidikian","year":"2022","journal-title":"Blood Cancer J."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"147776","DOI":"10.1016\/j.gene.2023.147776","article-title":"Frequency and prognostic influence of ASXL1 mutations and its potential association with BCR-ABL1 transcript type and smoke in chronic myeloid leukemia patients","volume":"886","author":"Mohammed","year":"2023","journal-title":"Gene"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1038\/s41375-022-01648-4","article-title":"ASXL1 mutations predict inferior molecular response to nilotinib treatment in chronic myeloid leukemia","volume":"36","author":"Rinke","year":"2022","journal-title":"Leukemia"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/bjh.17659","article-title":"Hierarchical distribution of somatic variants in newly diagnosed chronic myeloid leukaemia at diagnosis and early follow-up","volume":"194","author":"Romzova","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Hu, S., Chen, D., Xu, X., Zhang, L., Wang, S., Jin, K., Zheng, Y., Zhu, X., Jin, J., and Huang, J. (2022, January 10\u201313). Targeted Next-Generation Sequencing Identifies Additional Mutations Other than BCR\u2237ABL in Chronic Myeloid Leukemia Patients: A Chinese Monocentric Retrospective Study. Proceedings of the 64th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), New Orleans, LA, USA.","DOI":"10.3390\/cancers14235752"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1182\/blood-2016-04-708560","article-title":"Spectrum of somatic mutation dynamics in chronic myeloid leukemia following tyrosine kinase inhibitor therapy","volume":"129","author":"Kim","year":"2017","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1038\/s41467-021-23097-w","article-title":"Clonal evolution and clinical implications of genetic abnormalities in blastic transformation of chronic myeloid leukaemia","volume":"12","author":"Ochi","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"8581","DOI":"10.2147\/OTT.S257661","article-title":"Integrative Genomic Analysis Reveals Cancer-Associated Gene Mutations in Chronic Myeloid Leukemia Patients with Resistance or Intolerance to Tyrosine Kinase Inhibitor","volume":"13","author":"Wu","year":"2020","journal-title":"OncoTargets Ther."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1182\/blood.2025030259","article-title":"Impact of ASXL1 at diagnosis in patients with CML receiving frontline potent TKIs: High risk of kinase domain mutations","volume":"146","author":"Shanmuganathan","year":"2025","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1182\/bloodadvances.2019000943","article-title":"Mutation accumulation in cancer genes relates to nonoptimal outcome in chronic myeloid leukemia","volume":"4","author":"Awad","year":"2020","journal-title":"Blood Adv."},{"key":"ref_29","first-page":"42","article-title":"Who 2016 Definition of Chronic Myeloid Leukemia and Tyrosine Kinase Inhibitors","volume":"37","author":"Kuzu","year":"2019","journal-title":"Turk. J. Hematol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1182\/blood-2002-09-2790","article-title":"Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy","volume":"101","author":"Cortes","year":"2003","journal-title":"Blood"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.exphem.2022.09.003","article-title":"Role of ASXL1 in hematopoiesis and myeloid diseases","volume":"115","author":"Gao","year":"2022","journal-title":"Exp. Hematol."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Alves, R., Gon\u00e7alves, A.C., Rutella, S., Almeida, A.M., Rivas, J.D.L., Trougakos, I.P., and Ribeiro, A.B.S. (2021). Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia\u2014From Molecular Mechanisms to Clinical Relevance. Cancers, 13.","DOI":"10.3390\/cancers13194820"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1111\/cas.70007","article-title":"CML With Mutant ASXL1 Showed Decreased Sensitivity to TKI Treatment via Upregulation of the ALOX5-BLTR Signaling Pathway","volume":"116","author":"Miyashita","year":"2025","journal-title":"Cancer Sci."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1701719","article-title":"Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease","volume":"377","author":"Jaiswal","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"SCI-10","DOI":"10.1182\/blood.V126.23.SCI-10.SCI-10","article-title":"Clonal Events in Normal Aging Hematopoiesis","volume":"126","author":"Busque","year":"2015","journal-title":"Blood"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1038\/s41375-018-0157-2","article-title":"Frequent ASXL1 mutations in children and young adults with chronic myeloid leukemia","volume":"32","author":"Ernst","year":"2018","journal-title":"Leukemia"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1182\/blood-2024-193991","article-title":"The Combination of Asciminib with ATP Competing Tyrosine Kinase Inhibitors Might Overcome the Negative Impact of ASXL1 Mutations on Molecular Response in Newly Diagnosed CML Patients","volume":"144","author":"Ernst","year":"2024","journal-title":"Blood"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/13\/2041\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T06:05:31Z","timestamp":1782281131000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/13\/2041"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,24]]},"references-count":37,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["cancers18132041"],"URL":"https:\/\/doi.org\/10.3390\/cancers18132041","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,24]]}}}